Compugen (NasdaqCM:CGEN) Q3 2025 Earnings Call November 10, 2025 08:30 AM ET Company ParticipantsEran Ophir - President and CEODavid Silberman - CFOYvonne Naughton - VP and Head of Investor Relations and Corporate CommunicationsMichelle Mahle - CMOConference Call ParticipantsStephen Willey - AnalystDaina Graybosch - Senior Research AnalystSwayampakula Ramakanth - AnalystAsthika Goonewardene - AnalystLeland Gershell - Senior AnalystOperatorLadies and gentlemen, thank you for joining us today. Welcome to the ...

Compugen (NasdaqCM:CGEN) Q3 2025 Earnings Call November 10, 2025 08:30 AM ET Company ParticipantsEran Ophir - President and CEODavid Silberman - CFOYvonne Naughton - VP and Head of Investor Relations and Corporate CommunicationsMichelle Mahle - CMOConference Call ParticipantsStephen Willey - AnalystDaina Graybosch - Senior Research AnalystSwayampakula Ramakanth - AnalystAsthika Goonewardene - AnalystLeland Gershell - Senior AnalystOperatorLadies and gentlemen, thank you for joining us today. Welcome to the ...

Compugen (NasdaqCM:CGEN) Q3 2025 Earnings Call November 10, 2025 08:30 AM ET Speaker0Ladies and gentlemen, thank you for joining us today. Welcome to the Compugen Third Quarter 2025 Results Conference Call. At this time, all participants are in the listen-only mode. An audio webcast of this call is available in the investor section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded. I would now like to introduce Yvonne Naughton, VP, Head of Investor Relations and Corporate Co ...

Accessibility StatementSkip Navigation Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatm ...

Core Insights - Compugen Ltd. is set to release its third quarter 2025 financial results on November 10, 2025, before U.S. markets open, followed by a conference call at 8:30 AM ET to discuss the results and provide a corporate update [1]. Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes a predictive AI/ML-powered computational discovery platform named Unigen to identify new drug targets and biological pathways for cancer immunotherapies [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement, while GS-0321, an anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at activating the immune system against cancer [3]. - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3].

Core Insights - Compugen Ltd. is advancing its clinical-stage cancer immunotherapy with the presentation of a first-in-human trial for the anti-IL18BP antibody, COM503 (GS-0321), at the upcoming SITC Annual Meeting in November 2025 [1][2]. Company Overview - Compugen is a clinical-stage therapeutic discovery and development company that utilizes AI/ML-powered computational discovery to identify new drug targets and biological pathways for cancer immunotherapies [2]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [2]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [2]. - GS-0321 (previously COM503) is a high-affinity anti-IL-18 binding protein antibody in Phase 1 development, licensed to Gilead [2]. - Compugen's pipeline includes early-stage immuno-oncology programs aimed at activating the immune system against cancer [2]. - The company is headquartered in Israel with additional offices in San Francisco, CA, and is listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [2].

Core Insights - Compugen Ltd. is set to present a pooled analysis of data from three Phase 1 trials of COM701 for treating heavily pretreated platinum-resistant ovarian cancer patients at ESMO 2025 in Berlin [1][2] Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes AI/ML for predictive computational drug target discovery [2] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [2] - Compugen's pipeline includes early-stage immuno-oncology programs aimed at activating the immune system against cancer [2] - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [2]

Company Overview - Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in predictive computational drug target discovery using AI/ML technologies [3] - The company is headquartered in Israel and has an office in San Francisco, CA, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3] Upcoming Financial Results - Compugen will release its second quarter 2025 financial results on August 6, 2025, before U.S. financial markets open [1] - A conference call and webcast will be held at 8:30 AM ET to review the results and provide a corporate update [1] Product Pipeline - Compugen has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3] Research Programs - The company has a therapeutic pipeline focused on early-stage immuno-oncology programs aimed at activating the immune system against cancer through new mechanisms [3]

Core Insights - Compugen Ltd. has initiated the first patient dosing in a global randomized sub-trial of its adaptive platform trial, MAIA-ovarian, focusing on the maintenance therapy with COM701 for relapsed platinum-sensitive ovarian cancer [1][2][5] Group 1: Trial Details - MAIA-ovarian is designed to evaluate the safety and efficacy of COM701 as maintenance monotherapy or in combination therapy for patients with relapsed platinum-sensitive ovarian cancer [3][5] - Sub-trial 1 is a double-blind, randomized placebo-controlled trial involving 60 patients, randomized in a 2:1 ratio to receive COM701 or placebo [3][5] - An interim analysis of sub-trial 1 is scheduled for the second half of 2026, which may inform a registration path for COM701 monotherapy [2][5] Group 2: Clinical Rationale and Expectations - The trial is supported by strong biological rationale, with high PVRIG pathway expression levels observed in ovarian cancer, indicating a significant unmet medical need [2][3] - Historical data suggests a benchmark for progression-free survival of around six months, with a clinically meaningful improvement of three months over placebo anticipated [2][5] - COM701 has shown durable responses in previous clinical data, including a response duration of over 18 months in a patient treated as a single agent [2][5] Group 3: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company utilizing AI/ML for predictive computational target discovery, focusing on cancer immunotherapies [4][6] - The company has two proprietary product candidates in Phase 1 development: COM701 and COM902, targeting different pathways in cancer treatment [4][6] - Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [6]

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that utilizes AI/ML driven predictive computational research to enhance understanding of complex cancer biology [1][2]. Group 1: Conference Presentations - Compugen will present at the 2025 Annual Congress of the European Association for Cancer Research in Lisbon, Portugal, from June 16-19, with a poster titled "Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes" [2]. - Another presentation will occur at the International Society for Computational Biology and European Conference on Computational Biology in Liverpool, UK, from July 20-24, featuring a poster titled "Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms" [2]. Group 2: Company Overview - Compugen employs a predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for cancer immunotherapy development [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3]. - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3].